Predict your next investment

ARUP Laboratories company logo
Corporation
MOBILE & TELECOMMUNICATIONS
aruplab.com

See what CB Insights has to offer

Investments

5

Portfolio Exits

1

Partners & Customers

10

About ARUP Laboratories

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and an enterprise of the University of Utah and its Department of Pathology. With more than 3,000 employees, ARUP offers in excess of 3,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays.

ARUP Laboratories Headquarter Location

500 Chipeta Way

Salt Lake City, Utah, 84108,

United States

800-522-2787

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ARUP Laboratories

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find ARUP Laboratories in 3 Expert Collections, including Conference Exhibitors.

C

Conference Exhibitors

5,302 items

M

Medical Devices

72 items

https://www.amdm.org/members.html

H

Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

ARUP Laboratories Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ARUP Laboratories Rank

Latest ARUP Laboratories News

Clinical Laboratory Service Market Size to Hit US$ 290 Bn by 2030

Nov 30, 2021

Companies Covered Qiagen, Quest Diagnostics, Inc, Sonic Healthcare, OPKO Health, Inc, Abbott, Charles River Laboratories; International, Inc, Cinven, Arup Laboratories, Laboratory Corporation of America Holdings (LabCorp), NeoGenomics Laboratories, Inc. North America dominated the market in 2020. This is attributed to the increased adoption rate of the latest technologies in the countries like US and Canada. The presence of high number of health care companies along with the various contract manufacturing organizations and contract research organizations is benefiting the market in this region. The rising investment by the private players in the research activities for the development of various drugs for the treatment of chronic disease such as cancer, leukemia, lymphoma, muscular degeneration, and diabetes has necessitated the need for the efficient management of data and hence, the demand for the Clinical laboratory service increased rapidly in the region. Asia Pacific is expected to be the most opportunistic market during the forecast period. The rising government expenditure to develop strong healthcare infrastructure and government policies to attract FDIs is expected to play a significant role in the growth of the Clinical laboratory service market in the region. The presence of huge population and rising number of hospital admissions will foster the demand for the Clinical laboratory service systems in the Asia Pacific region, and will lead to the growth of the market during the forecast period. The rising prevalence of chronic diseases among the population will boost the demand for the health care services, pharmacies, and health insurances. Moreover, the increasing patient awareness, evolution to pathogens, advanced in area of healthcare and biotechnology in genomics & proteomics are the driving factors for the growth of the market. The high costs associated with the acquisition of the latest clinical laboratory service may hamper the growth of the market. Further, lack of adequate infrastructure and capital in the underdeveloped and developing nations may hamper the market growth during the forecast period. The introduction of latest technologies such as artificial intelligence and machine learning may provide growth prospects to the market players in the upcoming future, and drive the market growth. Based on the type, the clinical chemistry segment is the leading and the fastest-growing segment. This can be attributed to the increasing investments in the research activities for the development of life-saving drugs and diagnosis procedures to treat various chronic diseases prevalent among the global population. Based on the service provider, the hospital-based laboratories segment dominated the market. This can be attributed to the increased research activities and increased treatment of the cancer patients in the hospitals.According to the International Agency for Research on Cancer, in 2020, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe. Based on the application, the bioanalytical and lab chemistry services segment was the leading segment in 2020. The rising prevalence of diseases coupled with the increased number of hospital admissions has significantly contributed towards the growth of this segment in the past few years. Moreover, rising investments for the development of better and improve healthcare infrastructure is boosting the growth of the hospitals especially in the developing regions. Browse more related reports@ https://www.precedenceresearch.com/industry/healthcare Segments Covered in the Report By Test Type Preclinical & Clinical Trial Related Services Drug Discovery & Development Related Services Others Buy this Premium Research Report@  https://www.precedenceresearch.com/checkout/1387 You can place an order or ask any questions, please feel free to contact at  sales@precedenceresearch.com  | +1 9197 992 333 About Us Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us:

ARUP Laboratories Investments

5 Investments

ARUP Laboratories has made 5 investments. Their latest investment was in Techcyte as part of their Series A on August 8, 2021.

CBI Logo

ARUP Laboratories Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/18/2021

Series A

Techcyte

$21M

Yes

Undisclosed Investors, and Zoetis

6

3/17/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

10/28/2019

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

9/8/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/7/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/18/2021

3/17/2021

10/28/2019

9/8/2016

1/7/2016

Round

Series A

Series A

Series B - II

Series A

Series A

Company

Techcyte

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$21M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Undisclosed Investors, and Zoetis

Sources

6

10

10

10

10

ARUP Laboratories Portfolio Exits

1 Portfolio Exit

ARUP Laboratories has 1 portfolio exit. Their latest portfolio exit was Animal Reference Pathology on August 12, 2013.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/12/2013

Divestiture

1

Date

8/12/2013

Exit

Divestiture

Companies

Valuation

Acquirer

Sources

1

ARUP Laboratories Partners & Customers

10 Partners and customers

ARUP Laboratories has 10 strategic partners and customers. ARUP Laboratories recently partnered with DeepBio on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/25/2021

Partner

DeepBio

South Korea

DeepBio, ARUP to assess prostate cancer diagnosis SW in real-world workflow

DeepBio plans for further collaborations in various cancer diagnosis , prognosis , and prediction studies with ARUP Laboratories since the university accepted the joint research deal in May .

1

8/23/2021

Partner

Techcyte

United States

ARUP’s Investment Will Help Boost Development of Techcyte’s AI-Enabled Diagnostics Platform.

`` ARUP Laboratories 's partnership with Techcyte Inc. already has proven to be beneficial for both companies , '' ARUP Laboratories CEO Andy Theurer said .

1

7/16/2021

Vendor

DeepBio

South Korea

ARUP Collaborates with Deep Bio to Implement Artificial Intelligence in Clinical Research.

I am confident that this partnership with the prestigious ARUP Laboratories will bring us closer to the end users as our brand awareness will increase overseas , '' said Sun Woo Kim , the CEO and founder of Deep Bio Inc. .

1

7/14/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/10/2021

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/25/2021

8/23/2021

7/16/2021

7/14/2021

5/10/2021

Type

Partner

Partner

Vendor

Licensor

Vendor

Business Partner

DeepBio

Techcyte

DeepBio

Country

South Korea

United States

South Korea

Subscribe to see more

Subscribe to see more

News Snippet

DeepBio, ARUP to assess prostate cancer diagnosis SW in real-world workflow

DeepBio plans for further collaborations in various cancer diagnosis , prognosis , and prediction studies with ARUP Laboratories since the university accepted the joint research deal in May .

ARUP’s Investment Will Help Boost Development of Techcyte’s AI-Enabled Diagnostics Platform.

`` ARUP Laboratories 's partnership with Techcyte Inc. already has proven to be beneficial for both companies , '' ARUP Laboratories CEO Andy Theurer said .

ARUP Collaborates with Deep Bio to Implement Artificial Intelligence in Clinical Research.

I am confident that this partnership with the prestigious ARUP Laboratories will bring us closer to the end users as our brand awareness will increase overseas , '' said Sun Woo Kim , the CEO and founder of Deep Bio Inc. .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

ARUP Laboratories Team

1 Team Member

ARUP Laboratories has 1 team member, including former Chief Medical Officer, Jerry Hussong MD MBA.

Name

Work History

Title

Status

Jerry Hussong MD MBA

Chief Medical Officer

Former

Name

Jerry Hussong MD MBA

Work History

Title

Chief Medical Officer

Status

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.